FDA — authorised 8 May 1956
- Application: NDA010379
- Marketing authorisation holder: KING PHARMS
- Local brand name: CYTOMEL
- Indication: TABLET — ORAL
- Status: approved
🇺🇸 Triiodothyronine in United States
FDA authorised Triiodothyronine on 8 May 1956
Marketing authorisations
FDA
- Status: approved
Other Oncology approved in United States
Frequently asked questions
Is Triiodothyronine approved in United States?
Yes. FDA authorised it on 8 May 1956; FDA has authorised it.
Who is the marketing authorisation holder for Triiodothyronine in United States?
KING PHARMS holds the US marketing authorisation.